"BlueRock Therapeutics’ Phase 1 trial testing DA01 ... has completed enrolling its first group of patients with advanced Parkinson’s disease.
Meanwhile, enrolment for the second and final high-dose cohort of the open-label trial (NTC04802733) is still ongoing at sites in the U.S. and Canada."